Skip to main content

Immunotherapy clinical trials at UC Davis
9 research studies open to eligible people

  • A Study of Experimental Cellular Immunotherapy For Living Donor Kidney Transplants

    open to eligible people ages 18-70

    The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

    Sacramento, California and other locations

  • A Study of experimental Immunotherapy (Nivolumab) in Patients With Bladder or Upper Urinary Tract Cancer

    open to eligible people ages 18 years and up

    The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.

    Sacramento, California and other locations

  • Combination chemotherapy and experimental immunotherapy in the treatment of Stage III-IV HIV-associated Hodgkin lymphoma

    “Does adding immunotherapy (brentuximab vedotin) to combination chemotherapy (AVD) better treat (HIV)-associated Hodgkin lymphoma?”

    open to eligible people ages 18 years and up

    This phase II trial studies the side effects and the best dose of brentuximab vedotin and combination chemotherapy work in treating patients with stage III-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth by finding cancer cells and causing them to die. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.

    Clamart, and other locations

  • Experimental Immunotherapy MPDL3280A (Atezolizumab) and Radiation to treat patients with lung cancer

    “Study of Experimental Immunotherapy (Atezolizumab) and high dose radiation (SAR) in Inoperable Stage 1 Non-Small Cell Lung Cancer”

    open to eligible people ages 18 years and up

    This phase I trial studies the side effects and best dose of atezolizumab that can be given together with stereotactic body radiation therapy (SBRT) in treating patients with stage I non-small cell lung cancer that cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Giving atezolizumab together with stereotactic body radiation therapy may kill more tumor cells and be a better treatment for non-small cell lung cancer that cannot be removed by surgery.

    Sacramento, California and other locations

  • Experimental medicine, immunotherapy and targeted chemotherapy in patients with relapsed or refractory Non-Hodgkin Lymphoma

    “Help us test safety and dosing of combination treatment for Non-Hodgkin lymphoma that has returned or did not respond to treatment”

    open to eligible people ages 18 years and up

    This study will be conducted as a Phase Ib, open-label, non-randomized, single-institution study to evaluate the safety and tolerability of carfilzomib in combination with bendamustine and rituximab in patients with relapsed or refractory NHL and to determine the recommended phase II dose and preliminary efficacy of this combination. The study will have two phases: a dose-escalation phase to determine the maximal tolerated dose of carfilzomib in this combination where participants will be monitored for toxicity, tolerability and response and a dose-expansion phase that will determine the preliminary efficacy in patients with Mantle cell lymphoma or any other disease subtype in which there is a preliminary efficacy signal observed.

    Davis, California and other locations

  • Experimental treatment combination, immunotherapy, (pembrolizumab), and targeted chemotherapy, (trametinib) for lung cancer

    “Help us evaluate the effects of the combination of immunotherapy and targeted chemotherapy on non-small cell lung cancer”

    open to eligible people ages 18 years and up

    This phase Ib trial studies the side effects of pembrolizumab and trametinib in treating patients with non-small cell lung cancer and KRAS gene mutations that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib may work better in treating patients with non-small cell lung cancer.

    Sacramento, California

  • Study looking at immunotherapy treatment, after surgery and chemotherapy, to treat patients with lung cancer

    “Can immunotherapy help after surgery and chemotherapy to treat lung cancer?”

    open to eligible people ages 18 years and up

    This phase III ALCHEMIST trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Sacramento, California and other locations

  • Study looking at targeted chemotherapy and immunotherapy in treating patients with advanced/metastatic genitourinary tumors

    “Targeted chemotherapy and immunotherapy medicine with or without additional immunotherapy medicine to treat bladder/urothelial cancer”

    open to eligible people ages 18 years and up

    This phase I trial studies the side effects and best doses of cabozantinib-s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib-s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.

    Sacramento, California and other locations

  • Targeted chemotherapy (Ibrutinib) and immunotherapy (Nivolumab) to treat patients with previously-treated metastatic kidney cancer

    “Will targeted chemotherapy and immunotherapy work better in treating patients with metastatic kidney cancer?”

    open to eligible people ages 18 years and up

    This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with metastatic kidney cancer.

    Sacramento, California

Last updated: